Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Global Resistance of Imipenem/Relebactam Against Gram-Negative Bacilli: Systematic Review and Meta-Analysis Publisher



Abniki R1 ; Tashakor A2 ; Masoudi M2 ; Mansury D2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Current Therapeutic Research - Clinical and Experimental Published:2024


Abstract

Background: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from Klebsiella pneumoniae. Objective: The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli. Methods: After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus. Results: The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%–0.182%). Conclusions: The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary. © 2023 The Author(s)
Experts (# of related papers)
Other Related Docs
20. The Emergence of Qnr-Resistance Among Klebsiella Pneumoniae Spp in Zahedan, Iranian Journal of Pharmaceutical Sciences (2018)